Press Releases

 
Press Releases
  Date Title and Summary View
Dec 3, 2014
NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26th Annual Piper Jaffray Healthcare Conference being held at The New York Palace in New York City. The panel is sch...
Oct 1, 2014
NEW YORK, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Assembly) (Nasdaq:ASMB) announced today that on October 1, 2014, it entered into an agreement with institutional investors for the sale of 1,959,000 shares of its common stock at the price of $8.04 per share, resulting in $15.75 million in gross proceeds to the company. The sale...
Jul 25, 2014
NEW YORK, July 25, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB), a biopharmaceutical company developing innovative treatments for hepatitis B virus (HBV) and C. difficile-associated diarrhea (CDAD,) today announced that it will not pursue further development of VEN 307, an investigational product for the treatment of anal fissu...
Jul 14, 2014
NEW YORK, July 14, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that its stockholders have approved the issuance of common stock in connection with the merger between Ventrus and Assembly Pharmaceuticals, Inc. in an all-stock transaction. The merger was effective at 5:00 p.m. ET on July 11, 2014.  Ventrus...
Jun 9, 2014
NEW YORK, June 9, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) ("Ventrus" or the "Company") today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with the upcoming annual meeting of Ventrus stockholders.   The Company also announced that it is commencing the ...
May 19, 2014
~ New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide ~ Projected Multi-Billion Market Opportunity; No Curative Therapy Exists ~ Combined Teams Bring Experienced Leadership Capable of Driving Value ~ Anticipa...
= add release to Briefcase

Investor Data

© 2014 Assembly Biosciences

Back to top